Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists performed a landmark study comparing long-term outcomes in acute myeloid leukemia patients alive and disease-free two years after transplantation who received grafts from either cord blood transplantation or unrelated donors.
[Bone Marrow Transplantation]
6445218 6JTQUIQT items 1 apa 0 default asc 1 164498 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-b95a5c02537e3f233456d0d78bb20b75%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226JTQUIQT%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baron%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBaron%2C%20F.%2C%20Ngoya%2C%20M.%2C%20Labopin%2C%20M.%2C%20Cornelissen%2C%20J.%20J.%2C%20Ganser%2C%20A.%2C%20Forcade%2C%20E.%2C%20Sengeloev%2C%20H.%2C%20Soci%26%23xE9%3B%2C%20G.%2C%20Blaise%2C%20D.%2C%20Bornh%26%23xE4%3Buser%2C%20M.%2C%20Valerius%2C%20T.%2C%20Reinhardt%2C%20H.%20C.%2C%20Kr%26%23xF6%3Bger%2C%20N.%2C%20Ruggeri%2C%20A.%2C%20Nagler%2C%20A.%2C%20%26amp%3B%20Mohty%2C%20M.%20%282021%29.%20Comparison%20of%20long-term%20outcome%20for%20AML%20patients%20alive%20free%20of%20disease%202%20years%20after%20allogeneic%20hematopoietic%20cell%20transplantation%20with%20umbilical%20cord%20blood%20versus%20unrelated%20donor%3A%20a%20study%20from%20the%20ALWP%20of%20the%20EBMT.%20%3Ci%3EBone%20Marrow%20Transplantation%3C%5C%2Fi%3E%2C%201%26%23x2013%3B7.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41409-021-01387-7%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41409-021-01387-7%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3D6JTQUIQT%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20long-term%20outcome%20for%20AML%20patients%20alive%20free%20of%20disease%202%20years%20after%20allogeneic%20hematopoietic%20cell%20transplantation%20with%20umbilical%20cord%20blood%20versus%20unrelated%20donor%3A%20a%20study%20from%20the%20ALWP%20of%20the%20EBMT%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Baron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Ngoya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Labopin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20J.%22%2C%22lastName%22%3A%22Cornelissen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnold%22%2C%22lastName%22%3A%22Ganser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Forcade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henrik%22%2C%22lastName%22%3A%22Sengeloev%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Soci%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Blaise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Bornh%5Cu00e4user%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Valerius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%20Christian%22%2C%22lastName%22%3A%22Reinhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolaus%22%2C%22lastName%22%3A%22Kr%5Cu00f6ger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annalisa%22%2C%22lastName%22%3A%22Ruggeri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnon%22%2C%22lastName%22%3A%22Nagler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamad%22%2C%22lastName%22%3A%22Mohty%22%7D%5D%2C%22abstractNote%22%3A%22Since%20cord%20blood%20transplantation%20%28CBT%29%20has%20been%20associated%20with%20high%20graft-versus-leukemia%20effects%20and%20a%20low%20incidence%20of%20chronic%20graft-versus-host%20disease%20%28GVHD%29%2C%20we%20hypothesized%20that%20long-term%20outcomes%20might%20be%20better%20in%20CBT%20patients%20than%20in%20those%20given%20grafts%20from%20unrelated%20donors%20%28UD%29.%20Therefore%2C%20we%20performed%20a%20landmark%20study%20comparing%20long-term%20outcomes%20in%20acute%20myeloid%20leukemia%20%28AML%29%20patients%20alive%20and%20disease-free%202%20years%20after%20transplantation%20who%20received%20grafts%20from%20either%20CBT%20or%20UD.%20A%20total%20of%20364%20CBT%20recipients%2C%202648%20UD%2010%5C%2F10%20patients%20and%20681%20patients%20given%20grafts%20from%20UD%209%5C%2F10%20were%20included.%20Median%20follow-up%20was%206.0%20years.%20Five-year%20leukemia-free%20survival%20%28LFS%29%20from%20transplantation%20was%2086%25%20in%20CBT%20patients%2C%2084%25%20in%20UD%2010%5C%2F10%20patients%20%28P%5Cu2009%3D%5Cu20090.36%29%20and%2084%25%20in%20UD%209%5C%2F10%20patients%20%28P%5Cu2009%3D%5Cu20090.86%29.%20On%20multivariate%20analysis%2C%20donor%20type%20had%20no%20impact%20on%20LFS.%20Similarly%2C%20no%20impact%20of%20donor%20type%20was%20observed%20on%20relapse%20incidence%20or%20non-relapse%20mortality.%20Factors%20associated%20with%20poorer%20LFS%20on%20multivariate%20analysis%20included%20higher%20age%20at%20transplantation%20%28P%5Cu2009%3C%5Cu20090.001%29%2C%20male%20gender%20%28P%5Cu2009%3C%5Cu20090.001%29%2C%20second%20complete%20remission%20%28CR2%29%20versus%20CR1%20%28P%5Cu2009%3D%5Cu20090.05%29%2C%20secondary%20AML%20%28P%5Cu2009%3D%5Cu20090.01%29%2C%20antecedent%20of%20chronic%20GVHD%20%28P%5Cu2009%3C%5Cu20090.001%29%20and%20poor-risk%20cytogenetics%20%28P%5Cu2009%3D%5Cu20090.01%29.%20In%20conclusion%2C%20our%20study%20shows%20that%20long-term%20outcome%20for%20AML%20patients%20in%20CR%20two%20years%20after%20transplantation%20is%20not%20impacted%20by%20donor%20type.%22%2C%22date%22%3A%222021-07-10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41409-021-01387-7%22%2C%22ISSN%22%3A%221476-5365%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41409-021-01387-7%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-07-13T18%3A31%3A59Z%22%7D%7D%5D%7D
Baron, F., Ngoya, M., Labopin, M., Cornelissen, J. J., Ganser, A., Forcade, E., Sengeloev, H., Socié, G., Blaise, D., Bornhäuser, M., Valerius, T., Reinhardt, H. C., Kröger, N., Ruggeri, A., Nagler, A., & Mohty, M. (2021). Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 1–7. https://doi.org/10.1038/s41409-021-01387-7 Cite
